BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Eligo Bioscience Gets $5M Grant to Advance Gene-Editing Skin Therapy Using Bacteria

by BiopharmaTrend   •   May 14, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Biotech   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

The funding supports development of Eligo’s topical gene delivery system, which programs skin-resident bacteria to locally produce therapeutic biologics.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Eligo Bioscience has been awarded a $5 million grant under the French government’s "Innovations in Biotherapies and Bioproduction" initiative, part of the France 2030 strategy and administered by Bpifrance (French public sector investment bank). The grant will support industrial scale-up of Eligo’s proprietary platform that delivers gene therapies directly to skin microbiota for local treatment of immune-mediated skin diseases.

The Paris-based company has developed a topical formulation that delivers protein-based nanoparticles containing DNA to commensal bacteria located within hair follicles. Once inside these bacteria, the payload programs them to produce therapeutic proteins in situ, enabling highly localized treatment. Eligo is currently advancing this platform toward late-stage clinical trials in moderate to severe acne vulgaris and expanding into broader immuno-dermatology indications.

Eligo’s "GEM" Platform

The platform is built around a class of programmable biologics called Eligobiotics, designed to deliver DNA payloads directly into target bacteria within the human microbiome. The platform supports three distinct applications:

  • SSAM (Sequence-Specific Anti-Microbials): A CRISPR-based approach that selectively kills harmful bacteria by inducing DNA breaks at specific genomic sites, sparing beneficial microbes.
  • GEM (Genome Editing of the Microbiome): A gene-editing strategy that modifies the DNA of target bacterial populations in situ, enabling durable changes to microbial function and supporting therapeutic reprogramming.
  • FAME (Function Addition to the Microbiome): A system for introducing genes into skin-resident or gut-resident bacteria to transiently produce therapeutic proteins locally, turning microbes into targeted delivery vehicles.

Together, these modalities allow Eligo to precisely reprogram the composition and behavior of microbial communities at the site of disease, offering a highly localized and modular approach to treating conditions linked to microbiome dysfunction.

To accelerate the bioproduction process, Eligo is partnering with Biose Industries, a microbial CDMO with GMP expertise in complex fermentation. The company’s recent milestones include the publication of its microbiome base-editing platform in Nature, foundational IP covering skin microbiome editing, and a $35 million Series B expansion.

The funding is intended to support exploration of new therapeutic payloads and the development of a broader pipeline addressing chronic inflammatory skin diseases, leveraging the proximity of follicle-dwelling microbes to skin immune cells. Eligo’s approach aims to convert these bacteria into controlled, site-specific producers of high-potency biologics.

Topics: Biotech   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.